[
  {
    "product_code": "BI 1810631",
    "product_name": "Zongertinib",
    "modality_name": "Small Molecule",
    "product_type": "NME",
    "therapeutic_area": "Oncology",
    "mechanism_of_action": "Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI)",
    "short_description": "HER2-selective TKI for NSCLC and other HER2-driven cancers",
    "description": "Zongertinib is an oral, irreversible HER2-selective TKI targeting HER2 gene alterations across multiple tumor types. It is being developed for NSCLC and other HER2-driven cancers.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Organic Spray Drying; Roller Compaction",
    "biel_category": "3A",
    "current_phase": "Registration",
    "project_status": "On Track",
    "lead_indication": "NSCLC (2nd Line)",
    "expected_launch_year": 2025,
    "patient_population": "Advanced NSCLC patients with HER2 mutations",
    "primary_packaging": "Bottle",
    "submission_status": "Submitted",
    "launch_geography": "US",
    "regulatory_details": {
      "NSCLC_2L": ["Breakthrough Therapy", "Fast Track"]
    },
    "ppq_status": "Completed",
    "critical_path_item": "OPS",
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": { "Cambrex": "completed", "Alphora": "backup_qualified" },
      "DP": { "Hovione": "completed", "ING": "launch_ready" }
    },
    "ds_volume_category": "Low (10-1,000 kg)",
    "dp_volume_category": "Low (1-10 million PCS)",
    "ds_suppliers": [
      { "name": "Cambrex", "site": "N/A", "role": "Primary", "status": "qualified" },
      { "name": "Alphora", "site": "N/A", "role": "Backup", "status": "qualified" }
    ],
    "dp_suppliers": [
      { "name": "Hovione", "site": "Portugal", "role": "Launch", "status": "launch_ready" },
      { "name": "ING", "site": "Ingelheim", "role": "Launch", "status": "launch_ready" }
    ],
    "operational_risks": {
      "high": ["If something goes wrong, impact on submission/launch timepoint highly likely"]
    },
    "timeline_risks": {
      "critical": ["Slight shift due to clinical activities"]
    },
    "clinical_trials": {
      "phase_1": {
        "trial_name": "NCT04886804",
        "indication": "HER2-driven cancers",
        "status": "Ongoing"
      }
    }
  },
  {
    "product_code": "BI 1015550",
    "product_name": "Nerandomilast",
    "modality_name": "Small Molecule",
    "product_type": "NME",
    "therapeutic_area": "Respiratory",
    "mechanism_of_action": "Preferential PDE4B inhibitor",
    "short_description": "First-in-class PDE4B inhibitor for pulmonary fibrosis",
    "description": "Nerandomilast is an oral PDE4B inhibitor developed to potentially stop disease progression in idiopathic pulmonary fibrosis. It is part of the global FIBRONEER™ Phase III program.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Twin Screw",
    "biel_category": "3A",
    "current_phase": "Registration",
    "project_status": "On Track",
    "lead_indication": "Idiopathic Pulmonary Fibrosis (IPF)",
    "expected_launch_year": 2025,
    "patient_population": "Patients with IPF",
    "primary_packaging": "Blister; Bottle",
    "submission_status": "Submitted",
    "launch_geography": "Global",
    "regulatory_details": {
      "IPF": ["Breakthrough Therapy", "Orphan Drug"]
    },
    "ppq_status": "Completed",
    "critical_path_item": "Regulatory",
    "timeline_variance_days": -10,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": { "ING": "completed" },
      "DP": { "ING_SoL": "completed" }
    },
    "ds_volume_category": "Low (10-1,000 kg)",
    "dp_volume_category": "Medium (10-100 million PCS)",
    "ds_suppliers": [
      { "name": "ING", "site": "Ingelheim", "role": "Primary", "status": "qualified" }
    ],
    "dp_suppliers": [
      { "name": "ING_SoL", "site": "Ingelheim", "role": "Launch", "status": "qualified" }
    ],
    "operational_risks": {
      "high": ["Formulation risk due to TiO2 bridging requirement"]
    },
    "timeline_risks": {
      "critical": ["Potential delay due to BE study requirement"]
    },
    "clinical_trials": {
      "phase_3": {
        "trial_name": "FIBRONEER™",
        "indication": "IPF",
        "status": "Ongoing"
      }
    }
  },
  {
    "product_code": "BI 456906",
    "product_name": "Survodutide",
    "modality_name": "Biological",
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic",
    "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist",
    "short_description": "Injectable dual agonist for obesity and MASH",
    "description": "Survodutide is a novel injectable dual agonist targeting GLP-1 and glucagon receptors, developed for obesity and MASH. It is derived from oxyntomodulin and delivered via a PEN device.",
    "dosage_form": "Injectable",
    "route_of_administration": "Injectable",
    "base_technology": "Single-use isolator",
    "current_phase": "Phase III",
    "project_status": "Delayed",
    "lead_indication": "Obesity",
    "expected_launch_year": 2027,
    "patient_population": "Adults with BMI ≥ 27 kg/m²",
    "submission_status": "In Progress",
    "launch_geography": "Global",
    "regulatory_details": {
      "Obesity": ["Breakthrough Therapy", "Fast Track"]
    },
    "ppq_status": "At Risk",
    "critical_path_item": "CMC",
    "timeline_variance_days": 86,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": { "PPG": "halted" },
      "DP": { "Thermo Fisher": "ongoing", "Nemera": "device ramp-up" }
    },
    "ds_suppliers": [
      { "name": "PPG", "site": "N/A", "role": "Primary", "status": "halted" }
    ],
    "dp_suppliers": [
      { "name": "Thermo Fisher", "site": "N/A", "role": "Manufacturing", "status": "ongoing" },
      { "name": "Nemera", "site": "N/A", "role": "Device", "status": "ramp-up" }
    ],
    "device_partners": [
      { "name": "Nemera", "device_type": "PEN", "role": "Primary" }
    ],
    "operational_risks": {
      "high": ["DS PPQ halted", "High-risk formulation 2.0 development"]
    },
    "timeline_risks": {
      "critical": ["+86 day delay for Obesity", "+91 day delay for MASH"]
    },
    "clinical_trials": {
      "phase_3": {
        "trial_name": "Survodutide Obesity Trial",
        "indication": "Obesity",
        "status": "Ongoing"
      }
    }
  },
  {
    "product_code": "BI 690517",
    "product_name": "Vicadrostat",
    "modality_name": "Small Molecule",
    "product_type": "NME",
    "therapeutic_area": "Cardiovascular-Renal-Metabolic",
    "mechanism_of_action": "Selective aldosterone synthase inhibitor",
    "short_description": "ASi developed in combination with empagliflozin for CKD and HFpEF",
    "description": "Vicadrostat is a selective aldosterone synthase inhibitor developed in combination with empagliflozin for CKD and HFpEF. It aims to reduce aldosterone-driven disease progression.",
    "dosage_form": "Tablet",
    "route_of_administration": "Oral",
    "base_technology": "Twin Screw",
    "biel_category": "3A",
    "current_phase": "Phase III",
    "project_status": "On Track",
    "lead_indication": "Chronic Kidney Disease (CKD)",
    "expected_launch_year": 2028,
    "patient_population": "Patients with CKD and HFpEF",
    "primary_packaging": "Blister; Bottle",
    "submission_status": "Not Started",
    "launch_geography": "Global",
    "ppq_status": "Ongoing",
    "critical_path_item": "Operations",
    "timeline_variance_days": 0,
    "timeline_variance_baseline": "AD 2024",
    "ppq_details": {
      "DS": { "ING": "transfer ongoing" },
      "DP": { "ING_SoL": "transfer ongoing" }
    },
    "ds_volume_category": "High (>10 tn)",
    "dp_volume_category": "High (>100 million PCS)",
    "ds_suppliers": [
      { "name": "ING", "site": "Ingelheim", "role": "Primary", "status": "transfer ongoing" }
    ],
    "dp_suppliers": [
      { "name": "ING_SoL", "site": "Ingelheim", "role": "Primary", "status": "transfer ongoing" }
    ],
    "clinical_trials": {
      "phase_3": {
        "trial_name": "Vicadrostat CKD Trial",
        "indication": "CKD",
        "status": "Ongoing"
      }
    }
  }
]
